Fig. 5
PLEKHG4B is a downstream target of miR-661. (A) The potential binding sites of PLEKHG4B and miR-661 and the mutant PLEKHG4B sequences. (B) Dual-luciferase reporter assay and (C) RNA pull-down were used to verify the targeting relationship. (D) PLEKHG4B expression in HCC cells (Focus and HA22T) and normal cells (THLE3). (E) PLEKHG4B mRNA and (F) protein levels mediated by miR-661 inhibitor were detected using qPCR and western blotting, respectively. Original bands are presented in supplementary Fig. 4. (G) PLEKHG4B mRNA and (H) protein levels in HCC cells after circ_0008043 knockdown and miR-661 inhibition were detected using qPCR and western blotting, respectively. Original bands are presented in supplementary Fig. 5. (I) PLEKHG4B expression in 60 paired HCC tissues and adjacent non-tumor tissues. **P < 0.01. NS: no significance.
